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Infiltration of immune cells into the tumor microenvironment (TME) can regulate growth
and survival of neoplastic cells, impacting tumorigenesis and tumor progression.
Correlations between the number of effector immune cells present in a tumor and
clinical outcomes in many human tumors, including breast, have been widely described.
Current immunotherapies utilizing checkpoint inhibitors or co-stimulatory molecule
agonists aim to activate effector immune cells. However, tumors often lack adequate
effector cell numbers within the TME, resulting in suboptimal responses to these
agents. Chemerin (RARRES2) is a leukocyte chemoattractant widely expressed in
many tissues and is known to recruit innate leukocytes. CMKLR1 is a chemotactic
cellular receptor for chemerin and is expressed on subsets of dendritic cells, NK
cells, and macrophages. We have previously shown that chemerin acts as a tumor
suppressive cytokine in mouse melanoma models by recruiting innate immune defenses
into the TME. Chemerin/RARRES2 is down-regulated in many tumors, including breast,
compared to normal tissue counterparts. Here, using a syngeneic orthotopic EMT6
breast carcinoma model, we show that forced overexpression of chemerin by tumor
cells results in significant recruitment of NK cells and T cells within the TME. While
chemerin secretion by EMT6 cells did not alter their phenotypic behavior in vitro, it
did significantly suppress tumor growth in vivo. To define the cellular effectors required
for this anti-tumor phenotype, we depleted NK cells or CD8+ T cells and found that
either cell type is required for chemerin-dependent suppression of EMT6 tumor growth.
Finally, we show significantly reduced levels of RARRES2mRNA in human breast cancer
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samples compared to matched normal tissues. Thus, for the first time we have shown
that increasing chemerin expression within the breast carcinoma TME can suppress
growth by recruitment of NK and T cells, thereby supporting this approach as a
promising immunotherapeutic strategy.
Keywords: chemerin, RARRES2, breast cancer, leukocyte trafficking, immunotherapy, NK cells, T cells
INTRODUCTION
Breast cancer is one of the most common malignancies with
an estimated ∼266,000 new cases in 2018, according to SEER
estimates. The impact of infiltrating lymphocytes on breast
cancer patient outcomes has been studied in several contexts,
but in general is a favorable prognostic factor (1–3). The
presence of pre-existing immune effectors cells within the
tumor microenvironment (TME) within breast and other tumor
types can not only predict response to traditional cytotoxic
chemotherapy, but also immunotherapies (4–6). Compared
with tumor types that are more responsive to checkpoint
immunotherapy, however, there is a relative paucity of infiltrating
lymphocytes in breast cancer (7). Thus, strategies to enhance
recruitment of immune effector cells to the breast TME are
highly desirable.
Chemerin (retinoic acid receptor responder 2; RARRES2)
is a leukocyte chemoattractant initially discovered as being
highly up-regulated in the skin by the synthetic retinoid
tazarotene (8). Chemerin is widely expressed throughout tissues
and has myriad roles including the chemoattraction of innate
cells [e.g., NK cells, macrophages, dendritic cells (DCs)]
(9–11), functioning as an important antimicrobial agent in
the skin (12), and is able to induce angiogenesis in human
endothelial cells (13), suggesting chemerin may be a key
factor in early immune responses to infection, injury, and/or
inflammation. Chemerin is initially secreted in an inactive
pro-form, prochemerin, which is then cleaved by specific
proteases to become bioactive (9, 10). Chemerin has three
described serpentine cell membrane receptors: chemokine-like
receptor 1 (CMKLR1; ChemR23), C-C chemokine receptor-
like 2 (CCRL2), and G protein-coupled receptor 1 (GPR1)
(9, 14, 15). CMKLR1 is a chemotactic cellular receptor, while,
atypical chemoattractant receptor CCRL2 likely acts to sequester
and concentrate chemerin at sites of CCRL2 expression, such as
on activated endothelial cells (14–17). The function of GPR1 is
poorly understood, though it is reported to be expressed in the
CNS (18, 19).
Chemerin/RARRES2 has been studied in the context of
several different tumor types, with its dysregulation dependent
on the specific context. While we and others have reported on
several tumor types where chemerin/RARRES2 is significantly
down-regulated compared to normal tissue counterparts
(e.g., melanoma, lung, prostate, liver, adrenal, etc.) (20–25),
chemerin/RARRES2 has been shown to be up-regulated in
fewer tumor types (e.g., mesothelioma, squamous oral cancers)
(26–28). Several groups have correlated chemerin/RARRES2
expression levels in the TME with clinical outcomes, showing
improved patient survival in those patients with higher
expression levels (20–22, 24). Importantly, two of these studies
also evaluated the tumor biopsies for infiltrating leukocytes,
showing an increase and correlation between higher chemerin
levels and infiltrating NK cells in those patients with improved
overall survival (20, 21).
Our group was the first to show that in a mouse melanoma
model, overexpression and secretion of chemerin protein by
tumor cells increased total CD45+ tumor infiltrating leukocytes
(TIL), resulting in significantly suppressed tumor growth. In this
model, the effect was mediated by NK cells, as depletion via anti-
asialo GM1 resulted in complete abrogation of chemerin’s tumor
suppressive effects (22). In contrast, T cells were dispensable, as
RAG deficiency had no effect on the anti-melanoma effects of
chemerin in vivo (22). Importantly, neither engineered chemerin
expression nor incubation of mouse B16F0 melanoma cells with
exogenous, recombinant chemerin affected in vitro growth or
phenotype, suggesting chemerin’s main anti-tumor activity was
due primarily to its ability to recruit immune effector cells into
the TME.
Here, we studied the effect of chemerin/RARRES2
overexpression using the transplantable orthotopic syngeneic
EMT6 breast carcinoma model, which has been shown to
be responsive to immunomodulation in a variety of settings
(29–31). Utilizing a similar approach as in the B16 model, we
engineered EMT6 tumor cells to express and secrete functional
chemerin within the TME and then assessed the impact on
tumor growth and TIL. Chemerin overexpression significantly
suppressed tumor growth, which correlated with an increase in
TIL. Depletion studies identified NK and CD8+ T cells as key
effector leukocytes mediating chemerin’s anti-tumor activity,
suggesting an interplay between innate and adaptive arms.
In human breast tissue, chemerin/RARRES2 RNA expression
was significantly reduced in malignant samples compared to
normal controls. Taken together, these data suggest that loss of
chemerin/RARRES2 expression occurs in breast cancer during
tumorigenesis, potentially as an immune evasion mechanism,
and that restoring or enhancing chemerin levels within the TME
may prove efficacious in increasing TIL, thereby slowing or
reversing tumor progression in the clinic.
MATERIALS AND METHODS
Microarray Analysis
Publicly available breast cancer studies were evaluated using the
Oncomine database (www.oncomine.org), in which expression
data has been curated using statistical methods and standardized
normalization technique as previously described (32). The two
largest breast cancer studies comparing normal to malignant
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tissues were selected: Curtis et al. (http://www.ebi.ac.uk/ega/
studies/EGAS00000000083) (33) and TCGA (http://tcga-data.
nci.nih.gov/tcga) (34). The Curtis dataset contains 1,992
breast carcinoma samples and 144 paired normal breast
samples which were analyzed for the METABRIC project
using the Illumina HumanHT-12 V3.0 R2 Array. The TCGA
data included 532 invasive breast carcinomas and 61 paired
normal breast tissue samples using level 2 (processed) data
from the TCGA portal. The RARRES2 probe was selected
for normal, invasive/infiltrating ductal carcinoma (IDC) and
invasive/infiltrating lobular carcinoma (ILC) subsets, and gene
expression (mRNA) data were shown as log2 transformed,
median centered per array with p-values and fold change between
subsets generate by Oncomine.
Mice and Cell Lines
All mice were used in experiments were purchased from The
Jackson Laboratory. Wild type or Rag1 knockout (RAG KO;
#003145, Rag1tm1Mom) (35) female BALB/c mice were used as
indicated. Mice were maintained in the facilities at Washington
University under the direction and guidelines of the Division of
Comparative Medicine and used at approximately 9–12 weeks
of age. All animal experiments were conducted in accordance
with approved Washington University and National Institutes of
Health Institutional Animal Care and Use Committee guidelines
under an approved protocol (#20140232). The EMT6 mouse
mammary carcinoma cell line was purchased from ATCC (CRL-
2755). L1.2 cells transfected to express mouse CMKLR1 were
a kind gift from BA Zabel. Cell lines were grown in complete
media consisting of RPMI 1640 or DMEM supplemented with
10% FBS, sodium pyruvate, penicillin/streptomycin, and beta-
mercaptoethanol, with or without appropriate antibiotics for
selection. EMT6 cell lines (wild type and transduced) were
serially tested for mycoplasma and found to be negative using the
MycoProbe Mycoplasma Detection Kit (R&D Systems).
EMT6 Clone Production
The full-length gene that encodes mouse active chemerin,
mouse RARRES2, was inserted into the lentiviral transfer vector
pCDH1-MSC1-EF1-Puro (System Biosciences) using the NheI
and EcoRI restriction enzyme digestion sites. Empty vector
pCDH1-MSC1-EF1-Puro was used to produce control lentivirus.
293T/17 cells were grown in DMEM complete media in 10 cm
dishes for 16 h before transfected with packaging plasmid (18.2),
coat protein vector (pCMV-VSV-G) and transfer vector (pCDH-
Puro-wt RARRES2 or pCDH-Puro Empty vector) by using the
FuGENE R© HD Transfection Reagent (Promega) according to
themanufacturer’s protocol. The culture supernatants containing
lentiviruses were collected at 48 and 72 h post transfection.
The collected media were centrifuged at 300 × g to remove
cell debris and followed by filtration with 0.45µM filters. Viral
supernatants were either used immediately for cell transduction
or stored at −80◦C. To create EMT6 cell lines with constitutive
chemerin expression or control vector, viral supernatants added
with polybrene were used to infect wild type EMT6 cells. Starting
24 h infection, cells were selected with media containing 2µg/ml
puromycin for 3 days. Culture media containing puromycin was
replaced daily. Monoclonal cell populations were obtained by
limiting dilution.
In vitro Cell Line Evaluation
EMT6-pCDH-VEC or EMT6-pCDH-RARRES2 cells (1,000
cells/well) were plated in 96-well black walled plates (Corning).
Cells were grown in a 5% CO2 humidified incubator at 37
◦C
for the indicated days. On each day, alamar blue reagent
(ThermoFisher Scientific) was added directly to each well, the
plates were incubated at 37◦C for 1–4 h and the fluorescence
signal was measured according to the manufacturer’s protocol.
Data were shown as relative fluorescence values compared
with that of day 0, which was normalized to 1. Control and
chemerin-expressing EMT6 lines were plated at 200 k/ml/well
in 24 well plates and evaluated for chemerin secretion by
using a mouse chemerin ELISA (R&D Systems) on 48 h
conditioned media. Surface marker expression of control and
chemerin-expressing clones was evaluated by flow cytometry
with indicated monoclonal antibodies and appropriate isotype
controls (Biolegend). The functionality of secreted chemerin was
tested using conditioned media from control and chemerin-
expressing clones in chemotaxis assays. Briefly, 96 well HTS
Transwell Permeable Supports with 5µm pores (Corning) were
used according the manufacturers protocol; 250 k mCMKRL1+
L1.2 cells/75 µl were placed in the top chamber and 240 µl of
complete media+/− 3 nM recombinant, active mouse chemerin
(R&D Systems), or conditioned media in the bottom chamber.
Assays were left at 37◦C for ∼1–1.5 h. Migrated cells in the
bottom chamber were counted and percent migration calculated.
Tumor Inoculation
To evaluate the effect of constitutive chemerin secretion on
in vivo tumor growth, control or chemerin-expressing EMT6
breast tumor cells (0.5–1× 106) were inoculated subcutaneously
into 9–12 weeks old female BALB/c mice (JAX). Prior to
inoculation, EMT6 lines were grown to ∼60–80% confluence to
ensure log-growth kinetics, and viability was tested using trypan
blue and ensured to be ∼ >95% (or cells were not used). Tumor
growth was measured every 2–4 d by calipers, and size was
expressed either as the volume product of perpendicular length
by width in square millimeters, or by tumor size as indicated
by width × length (in square mm). Mice were euthanized when
tumor size reached ∼400 mm2 or when tumor sites ulcerated or
at indicated time points for TIL analyses.
In vivo Leukocyte Depletion
Mice were injected i.p. with 100 µl of anti-asialo GM1 or control
rabbit sera (Wako Chemicals) diluted 1:10 in PBS. Mice were
treated with antibodies on day 1, day 0 and every 2–3 days
after tumor inoculation. NK depletion efficiency was determined
by staining blood cells collected from the venous sinus. Briefly,
blood samples were isolated via retro-orbital bleed and washed
once with PBS. After centrifugation at 300 × g for 5min, cells
were stained with CD45, CD3, and DX5 or its isotype control
(Biolegend) and analyzed by FACS. For CD4+, CD8+ T cell
depletion, mice were injected i.p. with 250 µg/500 µl PBS of
anti-CD4 (clone GK1.5, BioXCell), anti-CD8β (Lyt 3.2) (clone
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53-5.8, BioXCell) or both, and rat IgG (Sigma) for control.
Antibodies were given weekly for 3 doses. Depletion efficiency
was determined by staining blood cells collected via retro-orbital
bleed with CD45, CD3, CD4, and CD8 antibodies (Biolegend)
and analyzed by FACS.
Evaluation of Tumor Infiltrating Leukocytes
At indicated time points, whole subcutaneous tumors were
resected en bloc including overlying skin and subcutaneous
tissues. Tumors were then processed into single cell suspensions
as previously described (22). Briefly, cells were counted using
trypan blue, and samples were blocked with PBS/FBS containing
1% rat serum and Fc block (anti-CD16/32; Biolegend). Stained
samples were analyzed on a BD Fortessa. For live/dead cell
discrimination, AmCyan LIVE/DEAD Fixable Dead Cell
Stain kit (Invitrogen) was used. Antibodies or appropriate
isotype controls were purchased from Biolegend and FlowJo
software (Tree Star) was used for analysis, with gating based
on appropriate isotype control staining, and percentages
expressed as shown of total live tumor cells or total live
CD45+ cells, as indicated. FACS analyses was used to define
the follow leukocyte subsets (all Live+CD45+): plasmacytoid
DCs (pDCs; Lin-CD11cintB220hi), conventional DCs (cDCs;
Lin- CD11chiB220low), CD4 (CD3+CD4+) T cells, CD8
(CD3+CD8a+) T cells, total T cells (CD3+CD4+CD8+), NK cells
(CD3-DX5+), monocyte/macrophages (Lin-CD11b+GR1−),
MDSCs (Lin-CD11b+GR1+), M1 (Lin-CD11chiF4/80+), and
M2 (Lin-CD11clowF4/80+) macrophages, CD19+ B cells
(CD3-CD19+). CD8+ T cell subsets were based on staining
with CD44 and CD62L: naïve (CD44lowCD62Lhi), effector
(CD44intCD62Llow), or memory (CD44hiCD62Llow).
Breast Tissue Microarrays
Tissue microarray (TMA) Breast Tissue FFPE sections were
collected from the St. Louis Breast Tissue Registry (funded by
The Department of Surgery at Washington University School
of Medicine, St. Louis, MO) under IRB-approved institutional
protocols. All patient information was de-identified prior to
sharing with investigators. Data and tissue was obtained in
accordance with the guidelines established by the Washington
University Institutional Review Board (IRB #201102394) and
WAIVER of Elements of Consent per 45 CFR 46.116 (d). Each
TMA core was 5µm thick and 2mm in diameter. Normal and
Tumor tissue was confirmed by a Board-Certified Pathologist
(Dr. Marshall Poger) using a stained Hematoxylin and Eosin
(H&E) section. Breast Tumor TMA section contained 37 IDC
cases and 8 ILC cases. Normal TMA Section contained 45 cases of
Terminal Ductal-Lobular Unit (TDLU) with 1 Tonsil and 4 Liver
cores for control and TMA positioning.
Quantitative Real-Time PCR
De-identified, paired RNA samples of malignant or non-
malignant human breast tissues were from the Siteman
Cancer Center Tissue Procurement Core, collected
under an IRB-approved research protocol (#201106191).
Quantitative Real-Time PCR was carried out using the
SYBR R© Green master mix (Bio-Rad) with the real-time
PCR primers for human chemerin and the housekeeping
gene GAPDH (sequence listed below). Measurements were
standardized to GAPDH using delta-delta Ct methods.
RNA from human liver was the positive control for
chemerin expression. RNA from RAJI cells was the negative
control. Data were expressed as fold expression levels of
negative control (RAJI, normalized to 1). Data shown
are mean ± SEM of two independent experiments using
identical starting RNA. Significant outliers identified by
Grubbs’ test were removed. The primers used for human
RARRES2 have been previously described (36): Forward:
5′- TGGAAGAAACCCGAGTGCAAA-3′; Reverse: 5′-
AGAACTTGGGTCTCTATGGGG-3′ Primers for human
GAPDH: Forward: 5′- GAGTCAACGGTTTGGTCGTATTG-3′;
Reverse: 5′- ATGTAGTTGAGGTCAATGAAGGGG-3′.
In situ Hybridization and Analysis
Manual chromogenic RNAScope (ACDBio) was performed using
company protocols on TMA tissue sections to detect target
RNA at single cell level. Tissue pre-treatment (Liver) included
baking for 1 h at 60 degrees Celsius, deparaffinization using
xylene and alcohol, RNAscope R© Hydrogen Peroxide (ACD#
322335) treatment for 10min at RT and protease treatment
(RNAscope R© Protease Plus ACD# 322331) for 30min at 40
degrees Celsius using the HybEZ Oven. Pre-treatment of non-
adherent cells (RAJI) included fixation by 10% NBF and
dehydration in series of 50, 70, and 100% ethanol. Cells were
treated with RNAscope R© Hydrogen Peroxide for 10min at
RT (ACD# 322335) and treated with RNAscope R© Protease III
(ACD# 322337) for 30min in 40 degrees Celsius using HybEZ
oven. For all tissue sections and non-adherent cells, ACDBio
pre-treatment protocol was used according to manufacturer’s
instructions. Detection of specific probe binding sites was with
RNAScope 2.5 HD Reagent kit—brown from ACD (Cat. No.
322310). Single ISH detection for human RARRES2 (ACD Probe:
457921), Positive Control Probe (PPIB - ACD Probe: 313901)
and Negative Control Probe (Dapb—ACD Probe: 310043) was
performed manually using RNAscope R© 2.5 HD Reagent Kit-
Brown (ACD, 322310). Target probes were hybridized for
2 h at 40 degrees Celsius using HybEZ oven and a series
of 6 amplification steps followed. A DAB-based chromogenic
reagent was used to detect the brown signal for the RARRES2
probe expression. The experimental procedure followed the
manufacturer’s instructions for single plex assay. Positive staining
was indicated by brown granular dots present in the nucleus
and/or cytoplasm.
Quantitative analysis was completed using regions of interest
(ROIs) and by random sampling. The ROIs for Normal and
Tumor breast tissue were manually selected by a Board-
Certified Pathologist (Dr. Marshall Poger) for imaging. Random
sampling was done by numbering each core on the TMA
section and using a random number generator to select which
TMA core was to be selected for analysis. HALO Software
by Indica Labs was used, specifically with the RNAScope
ISH Module per recommendation by ACD, with user-defined
thresholds. This module allowed the user to teach HALO
software to recognize hematoxylin (blue) and positive signal
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(brown granular dots). Positive signal is reported by number
of RNA copies. The Cytonuclear Module was used to teach
HALO Software to recognize hematoxylin (blue) to identify
nuclei. This generated a contrasted image allowing the user
to count the number of nuclei in the region of interest. ISH
module provided the user the number of RNA copies and
the Cytonuclear module provided the user the number of
cells. Thus, RNA copies per nuclei was determined allowing
analysis to be normalized to each nuclei. Slides were imaged
using a Nikon eclipse 50i microscope at 40x resolution. Three
comparable regions of interest for tumor (IDC and ILC) and
normal breast (TDLU) were subject to HALO Software for
image analysis.
Statistical Analysis
In vitro and in vivo tumor data was plotted using Prism software
v7 and further analyzed with InStat (GraphPad Software).
Differences between groups were evaluated by applying unpaired
Student’s t-test or non-parametric Mann-Whitney test, as
indicated. Paired human RNA samples were evaluated by a paired
student’s t-test. p<0.05 were considered significant.
RESULTS
Reduced RARRES2 Expression in Human
Tumors and Associated Poor Survival
Outcome
We and others previously showed that chemerin/RARRES2
expression is commonly down-regulated in multiple tumor
types, including breast cancer, compared to normal tissue
controls RARRES2 (22). Our published expression analysis was
limited to the publicly available GEO microarray datasets, thus,
to confirm reproducibility we sought to further investigate
chemerin expression in larger datasets. Here, we analyzed the
two largest breast cancer datasets with data for RARRES2
that were curated within the Oncomine database (32).
Chemerin/RARRES2 expression in both Curtis (Figure 1A)
and TCGA (Figure 1B) datasets was significantly decreased by
approximately 2.6- to 3.4-fold in tumor specimens compared
to normal (33, 34). Subsequently, to examine the association
between reduced RARRES2 expression and patient survival
outcome, we analyzed two sets of mRNA microarray data with
cohort sizes of 33 breast cancer patients and 135 early-stage
breast cancer patients, respectively, and found that low chemerin
levels significantly correlated with poor survival outcomes in
both groups (Figures 1C,D). By in situ hybridization (ISH)
comparing normal tissues to both invasive ductal carcinomas
(IDC) as well as invasive lobular carcinoma (ILC)—the two
most common histologic subtypes (37)—chemerin/RARRES2
was also down-regulated in the tumor samples (Figure 2).
Thus, across multiple datasets and analytical expression
methods, chemerin/RARRES2 was consistently down-regulated
in malignant breast cancer samples vs. controls, and reduced
chemerin/RARRES2 expression was correlated with poor
survival outcome.
Reduced Chemerin Expression in Human
Invasive Breast Cancers
Next, we wanted to independently validate the findings of our
public microarray analyses (Figure 1). We collected human
breast tissues from two different sources and, using two different
modalities, evaluated chemerin expression via measurement
of RARRES2 mRNA. Matched total RNA from normal and
malignant breast tissues (n = 13 patients with IDC) were
obtained from the Siteman Cancer Center Tissue Procurement
Core. De-identified frozen samples were collected under
approved consents, pathologically reviewed, and processed into
RNA per established protocols. RNA quantity and quality (i.e.,
RIN) was assured and validated primers for human RARRES2
(36) were used in real-time quantitative PCR. Expression of
RARRES2 mRNA in malignant breast tissues was significantly
reduced compared to patient matched, normal tissue (Figure 2).
Group mean/SEM of individually matched samples (Figure 2A)
are shown. Next, using samples collected from the St. Louis Breast
Tissue Registry under IRB-approved institutional protocols, we
then constructed normal (n = 45 cases) and malignant breast
tissue microarrays (TMA) incorporating both IDC (n= 37 cases)
and ILC (n= 8 cases). Utilizing ACDBio RNAscope, RNA in situ
hybridization (ISH) was performed. RARRES2 was undetectable
in both IDC and ILC samples compared to low but significant
RARRES2 signal in normal tissues (Figure 2B). Duplicate TMA
slides were used with positive and negative probes (ACDBio),
in parallel with human liver (RARRES2-positive) and Raji
cells (RARRES2-negative) as controls (Supplemental Figure 1).
Representative images are shown in Figure 2C, with the majority
of staining localized to epithelial components of the normal
breast tissue. Taken together, our data confirms significant down-
regulation of RARRES2 mRNA expression in both IDC and ILC
compared to normal breast tissues.
Forced Expression of Chemerin by EMT6
Breast Carcinoma
After confirming down-regulation of RARRES2 mRNA in
additional human studies, we then set out to favorably modulate
chemerin expression in the EMT6 mammary carcinoma model.
The EMT6 tumor line is a clonal isolate from a mouse
mammary carcinoma that arose from an implanted hyperplastic
alveolar nodule (38), and has been shown to be responsive
to immunomodulation (31, 39, 40). In order to test our
hypothesis that forced overexpression of chemerin by tumor cells
would act to recruit anti-tumor leukocytes and suppress tumor
growth, we used lentiviral transduction to introduce the mouse
RARRES2 gene into EMT6 tumor cells. The pCDH1-MSC1-
EF1-Puro (System Biosciences) vector was used to produce
either control (empty vector) or RARRES2 viral particles for
transduction. Control and chemerin-expressing EMT6 clonal
lines were generated by limiting dilution plating. Evaluation
of tumor-secreted chemerin was assessed by mouse chemerin
ELISA (R&D Systems). Both wild type and control-transduced
EMT6 lines showed no detectable chemerin by ELISA (not
shown), while RARRES2-transduced clones showed significant
production of secreted chemerin in the ng/ml range (Figure 3A).
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FIGURE 1 | RARRES2 microarray expression in breast tissues. The two largest mRNA studies comparing normal and malignant breast tissues were selected in
Oncomine (www.oncomine.org) for analysis. (A) Curtis, n = 2,136 total, (B) TCGA, n = 593 total. Both infiltrating ductal carcinoma (IDC) and infiltrating lobular
carcinoma (ILC) subsets show significantly lower expression of RARRES2 mRNA when compared to normal breast tissue. RARRES2 probes were selected and
relative expression by log2 median-centered intensity plotted for normal, IDC, and ILC subsets within each study. Oncomine calculated p-values and fold change
compared with normal subset are shown. Down-regulation of chemerin in breast cancer can be associated with poor survival outcomes. (C) mRNA microarray data
(accession # GSE6130-GPL887) from a cohort of 33 patients with breast cancer. mRNA microarray data was visualized using PROGgeneV2. The patients were
stratified according to chemerin expression (divided at 50th percentile), and survival plotted for each group. Hazard ratio: 0.42 (0.18–1.00), p-value: 0.049, indicating
that low chemerin levels significantly correlated with poor survival in this group. (D) mRNA microarray data (Caldas, Naderi Gene Exp 2007) from a cohort of 135
early-stage breast cancer, visualized using the UCSC Xena Browser. The patients were stratified according to chemerin expression (divided at 50th percentile), and
survival plotted for each group. p-value: 2.737 × 10−7, indicating that low chemerin levels significantly correlated with poor survival in this group.
From these, two clones, one with low (LC) and one with
high (HC) chemerin expression, were then selected for further
evaluation. In order to determine if the tumor-secreted chemerin
was functional and active, we utilized standard chemotaxis
assays using 5 um pore transwell chambers. Conditioned media
from both control and chemerin-expressing tumor lines was
evaluated. The mouse pre-B lymphocyte cell line L1.2 engineered
to express high levels of mouse CMKLR1 (10) was used to
assess chemerin-dependent migration. Conditioned media from
control transduced lines was unable to induce CMKLR1+
L1.2 cell chemotaxis, while conditioned media from chemerin-
expressing tumor lines triggered robust migration comparable to
recombinant, active chemerin (3 nM, R&D Systems). Chemotaxis
of CMKRL1+ L1.2 cells in the HC clone was ∼2-fold compared
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FIGURE 2 | Chemerin RNA expression in human breast tissue. (A) Real-time quantitative PCR (RT-qPCR) of chemerin mRNA expression in matched normal and
malignant breast tissue. RNA was isolated from paraffin embedded tissues and assessed for concentration, purity, and integrity. Chemerin expression was normalized
to GAPDH loading control for each sample (**p = 0.0159 compared to normal breast tissue, n = 13 for each subset using two tailed paired t-test). Inset shows group
means/SEM. (B) Quantified RARRES2 RNA expression in normal breast, IDC breast, and ILC breast tumor tissue microarrays (TMA) using RNAScope in-situ
hybridization (ISH). Three comparable regions of interest (ROI) from each case of normal breast (n = 7) or tumor (IDC and ILC; n = 7 each) were subject to HALO
Software for image analysis. The ROIs for normal and tumor breast tissue were manually selected for imaging/analysis. RNA expression is normalized to the number of
nuclei in each image to determine RNA copies per nuclei. (**p = 0.0001 compared to normal breast using a one sample t-test). Results are representative of two
TMAs containing (1) 45 normal cases and (2) 37 IDC cases and 8 ILC cases. (C) Representative ISH images for RARRES2 RNA expression in normal, IDC breast, and
ILC breast tissue. Slides were imaged using a Nikon eclipse 50i microscope at 40X resolution; 100mm bar shown. Positive staining is indicated by brown granular
dots present in the cell nucleus and/or cytoplasm.
to the LC clone, in line with measured secreted chemerin levels
(Figure 3B). In order to assess the effects of chemerin production
and secretion on in vitro tumor cell proliferation, we utilized
an alamar blue assay (ThermoFisher) and measured growth as
a function of fluorescence signal over several days. There were no
consistent differences between control or chemerin-expressing
EMT6 clones (Figure 3C). Next, we looked at expression of
several common surface markers involved in tumor-immune
recognition (MHC class I, CD1d, PD-L1) as well as tumor cell
migration and invasion (CD44) (41). While CMKLR1 has been
reported to be expressed on some human tumors (42), we did not
see detectable surface levels of CMKLR1 above isotype control,
in line with our prior studies of the mouse melanoma line B16F0
(22). Figure 3D shows comparable phenotypic expression of
these markers between control and chemerin-expressing tumor
lines. These data show that transduction with RARRES2 and
expression/secretion of chemerin by EMT6 tumor cells does
not appear to meaningfully impact in vitro growth or the
immunophenotype of key surface proteins, and that secreted
chemerin is functionally active and can induce migration of
CMKLR1+ cells.
Chemerin Overexpression Suppresses
EMT6 Tumor Growth in vivo
Given that chemerin-overexpression failed to impact EMT6
proliferation in vitro or expression of MHC class I, CD1d,
CD44, or PD-L1, we next wanted to study the impact of
chemerin expression in the TME on in vivo growth. Using WT
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FIGURE 3 | Evaluation of chemerin-expressing EMT6 tumor lines. The mouse breast carcinoma line EMT6 was used to study the impact of forced chemerin
expression on tumor growth. Wild type EMT6 cells were transduced using the lentiviral transfer vector pCDH1-MSC1-EF1-Puro, with the full length mouse RARRES2
gene inserted (RARRES2) or not (control). (A) Clonal cell lines (n = 17) were generated and chemerin protein secretion in clonal conditioned media samples was
quantified by ELISA. Clones with low (LC) and high chemerin (HC) secretion (indicated by boxes) were selected for subsequent in vitro and in vivo analysis. (B)
Chemotaxis assays using CMKLR1+L1.2 transfectants and 5 micron transwell chambers were performed to confirm functionality of EMT6-secreted chemerin.
Conditioned media was used from control and chemerin-expressing tumor lines (LC, HC). Media alone (NEG) and 3 nM recombinant mouse chemerin (POS; R&D
Systems) were used as controls. The normalized “percent of input” migration is shown; mean/SEM plotted for duplicate wells for each condition. Representative
proliferation and chemotaxis assays are shown, and were each performed several times prior to tumor inoculation in mice. (C) Control and high chemerin-expressing
lines were evaluated for in vitro cell proliferation using an alamar blue assay; relative fluorescence values normalized to 1 on day 0 are shown. (D) Surface expression
of CMKLR1, MHC class I, CD-1d, CD44, and PD-L1 was determined by FACS for control and high chemerin-expressing EMT6 tumor lines. For each marker
indicated, the appropriate isotype control antibody (gray) is shown.
female BALB/c recipients, control or chemerin-expressing EMT6
tumor cells were orthotopically implanted into the mammary
fat pad as described (22). To determine if the level of chemerin
secretion from transduced clones affected in vivo tumor growth,
we implanted low-chemerin (LC) and high-chemerin (HC)-
secreting clones. The in vivo growth of HC EMT6 tumors was
significantly suppressed compared to LC- or control-EMT6 cells
(Figure 4A), with some mice showing complete suppression of
in vivo tumorigenesis. To confirm this was not an effect of
clonality, we utilized completely independent, bulk transduced
EMT6 tumor cell lines (i.e., polyclonal) and saw a similar
significant reduction in in vivo tumor growth (Figures 4A,B).
This might suggest that an adequate concentration gradient of
chemerin within the TME needs to be established to recruit
anti-tumor leukocytes and suppress tumor growth. Indeed, there
was an approximately 2-fold increase in the total CD45+ tumor
infiltrating leukocytes (TIL) relative to tumor cells in HC-EMT6
tumors compared to LC- or control-EMT6 tumors at time of
euthanasia (Figures 4C,D).We next looked at the composition of
infiltrating leukocyte subsets in the TME by flow cytometry and
identified significant increases in the relative percentages of total
T cells, CD4+ T cells, and NK cells among total CD45+ cells in
HC-EMT6 tumors compared with controls by day 35 of tumor
growth (Figures 4E,F; Supplemental Figure 2). CD8+ T cells
were also enriched among the total CD45+ cells in theHC-EMT6
tumors by day 35, compared to day 14 (Figure 4G). However,
no significant differences in percentages of total T cells, CD4+
or CD8+ T cell subsets, B cells, NK cells, cDCs, pDCs, MDSCs,
or macrophages among CD45+ TILs were detected between the
two groups at an earlier time point in tumor growth (day 14,
not shown), potentially suggesting that sufficient time is needed
to establish an adequate concentration gradient of chemerin
and resultant chemoattraction of effector cells. No significant
differences were seen in either CD4+ or CD8+ regulatory T
cells (CD25+FoxP3+) between the groups at either early or late
time points (Figures 4H,I). Taken together, these data show high-
chemerin expression within the EMT6 TME results in significant
tumor growth suppression and a favorable anti-tumor skewing of
both NK cells and T cells, as a percentage of total TIL.
The Anti-Tumor Effects of Chemerin Are
Mediated by NK Cells and T Cells
Our initial in vivo EMT6 tumor data identified a correlation
among high-chemerin expression by EMT6 tumors, increased
NK cells and T cells in the TIL population and suppressed tumor
growth. (Figure 4). To further define the cellular mechanism
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FIGURE 4 | High chemerin expression by EMT6 tumors suppresses in vivo growth and results in altered TIL makeup. (A) High and low chemerin-expressing EMT6
clones were used in parallel with a control transduced EMT6 cells. 0.5–1 × 106 tumor cells were inoculated subcutaneously into 9–12 weeks old female BALB/c
mice. Tumor growth was serially assessed using calipers. Mean/SEM shown with groups n = 10 per indicated line. Two-way ANOVA with Tukey’s multiple
comparisons test show no significant differences between control and LC groups, with p-value as indicated for differences compared to HC group. (B) Representative
images of mice from control and chemerin-expressing groups showing significant in vivo suppression of tumorigenesis, 20 days post-inoculation. (C) Percent CD45
positive of total tumor cells by FACS analysis within the tumor microenvironment (TME) shown for (A) tumors (n = 2–3/group) resected at time of euthanasia (day 26).
(Continued)
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FIGURE 4 | (D) Graph of fold increase showing CD45+ cells per total tumor cells, comparing HC-EMT6 tumors to control-EMT6 tumors resected at time of
euthanasia (day 14, n = 6/group; day 26, n = 2–3/group; day 35, n = 3/group) and analyzed via FACS. Graph depicts two independent experiments; tumors
collected on day 14 and day 35 are derived from the same experiment. (E,G–I) In a separate cohort of mice, we euthanized animals at pre-defined timepoints for TIL
analysis. Of the mice that were initially inoculated; six mice per group were euthanized on day 14 for FACS analysis, and an additional three mice per group were
euthanized on day 35 for further FACS analysis. Graphs show mean/SEM values; statistical significance (defined in Methods) was determined between groups using a
2-sided unpaired t-test. (E) FACS analysis of TIL from control-EMT6 or HC-EMT6 tumors (n = 3/group) resected on day 35. (F) FACS analysis of TIL from
control-EMT6 or HC-EMT6 tumors resected on day 26 (n = 2–3/group). (G) FACS analysis of TIL from HC-EMT6 tumors (n = 6) resected on day 14 compared to TIL
from HC-EMT6 tumors resected on day 35 (n = 3), specifically showing the CD8+ T cell population. (H) FACS analysis of TIL from control-EMT6 or HC-EMT6 tumors
resected on day 14 (n = 6/group), specifically showing CD4+ and CD8+ regulatory T cell populations (CD25+FoxP3+). (I) FACS analysis of TIL from control-EMT6 or
HC-EMT6 tumors resected on day 35 (n = 3/group), specifically showing CD4+ and CD8+ regulatory T cell populations (CD25+FoxP3+). *P < 0.05.
of action of chemerin-dependent tumor growth suppression,
we selectively depleted candidate lymphocyte subsets (or used
genetically-modified subset-deficient animals) and evaluated
HC-EMT6 tumor growth. We first used anti-asialo GM1 to
deplete NK cells. Control and chemerin-expressing lines were
inoculated into mice treated with control sera or anti-asialo GM1
(Wako Chemicals) sera. Anti-asialo GM1 treatment had no effect
on control EMT6 tumor growth in vivo, while similar treatment
resulted in the complete abrogation of tumor suppression in
the chemerin-expressing tumors (Figure 5A). There were no
significant differences noted between the growth of control-
EMT6 tumors (+/- anti-asialo GM1) and NK cell-depleted
chemerin-expressing tumors (Figure 5A). The extent of NK cell
depletion was confirmed by analysis of peripheral blood prior to
tumor inoculation (Figure 5B; Supplemental Figure 3A). Next,
to explore the potential role of adaptive immunity in chemerin-
dependent EMT6-tumor growth suppression, we used Rag1
KO mice, which lack mature T and B cells (35). Growth
suppression by tumor-secreted chemerin was only seen in wild
type mice and was completely abrogated in RAG KO mice
(Figure 5C), suggesting a requirement of the adaptive immune
response in this model. Given the lack of change in B cells
and the significant increase in T cells in the TIL population in
chemerin-expressing tumors, we then set out to define specific
T cell subsets responsible for the chemerin-dependent anti-
tumor effect. We used specific antibodies to deplete CD4+
and/or CD8+ T cells as indicated. Control antibody treatment
did not affect suppression of tumor growth in chemerin-
expressing tumors. However, depletion of CD8+ T cells in
chemerin-expressing tumors—either alone or in combination
with CD4+ T cell depletion—resulted in growth comparable
to control tumors (Figure 5D). T cell subset depletion was
confirmed by analysis of peripheral blood, which was essentially
complete (Figure 5E; Supplemental Figure 3B). Interestingly,
CD4+ T cell depletion alone in chemerin-expressing tumors
resulted in improved tumor growth suppression (Figure 5D).
Recently published data show that CD4+ T cell depletion
in the EMT6 model results in a significant increase in
CD45+ TIL, with a ∼3-fold increase in IFNγ+CD8+ T cells
in the draining lymph nodes compared to controls. CD4+
T cell depletion—as in our model—resulted in significantly
reduced tumor growth, hypothesized to be due to a reduction
in immunosuppressive regulatory CD4+ T cells (40). In
line with this data, analysis of our control and T cell
depleted cohorts showed a significant increase (∼3-fold) in
total CD45+ TIL only in the CD4+ T cell depleted mice
(not shown). Taken together, these data suggest critical roles
for both NK and CD8+ T cells in mediating chemerin
tumor suppression.
DISCUSSION
Chemerin is a multifunctional protein with wide tissue
expression and myriad roles in host defense, implicated
in antibiosis, angiogenesis, as well as chemoattraction of
leukocytes (43). Several groups have described its dysregulation
in the context of tumorigenesis, with the majority—but not
all—showing decreased chemerin/RARRES2 expression within
malignant tissues (20–22, 42, 44–48). Our group was the first to
show tumor suppression via therapeutic modulation of chemerin
in a mouse tumor model, with now several studies confirming
the role of chemerin as a tumor suppressor in various settings
(22, 45, 46, 48, 49). Importantly, two independent studies showed
not only improved patient survival but also increased immune
effector cell infiltrates in tumor samples with higher chemerin
expression (20, 21). Our prior studies in the B16F0 mouse
melanoma model showed increases in tumor-infiltrating NK and
T cells with forced overexpression of chemerin by tumor cells,
with suppression mediated by NK cells in that model (22). This
led us to hypothesize that chemerin may play a key role in
tumor immune surveillance and, further, that malignant tissues
may selectively down-regulate chemerin/RARRES2 as a means of
immune escape (Figure 6).
Human breast cancers have variable levels of infiltrating
immune cells, with ER/PR+HER2- subtypes typically showing
the lowest (2). Breast cancer subtypes with high TILs may also
show higher expression of checkpoint molecules such as PD-
1 and CTLA-4 (50), which may play a role in higher response
rates to checkpoint inhibitors in these tumor subtypes (e.g.,
ER/PR-HER2-, HER2+) (51). Decreased levels of TIL have been
described in metastatic breast tumors compared to matched
primary tumors (52), suggesting a role for immune escape in
breast cancer progression. Thus, strategies to increase TIL and
improve immunosurveillance in breast cancer are attractive from
a therapeutic standpoint.
Here, we present—for the first time to our knowledge—
studies focused on the expression and role of chemerin/RARRES2
in human breast tissues and a mouse model of breast cancer.
Using the fully immune competent mouse EMT6 breast tumor
model, we have shown that overexpression and secretion of
chemerin by tumor cells significantly suppressed tumor growth
in vivo. As in our melanoma model, chemerin appears to have no
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FIGURE 5 | Depletion of NK, T cells abolishes chemerin-induced tumor suppression. (A) Control or high chemerin-expressing (HC) EMT6 cells were inoculated in wild
type BALB/c mice (n = 4–5/group). NK cell depletion was accomplished using anti-asialo GM1 (control rabbit sera was used as a negative control) (Wako Chemicals).
(B) Depletion of blood NK cells was confirmed in each experiment at either day −1 or day 0 (time of inoculation). (C) Control and chemerin-expressing lines were
inoculated in both wild type (WT; n = 10/group) and Rag-1 knockout (RAG KO, Jackson Labs; n = 7/group). (D) Antibody depletion of T cell subsets (CD4, CD8) was
accomplished using i.p., injection of 250 ug/500 ul PBS of anti-CD4 (clone GK1.5, BioXCell), anti-CD8β (Lyt 3.2) (clone 53-5.8, BioXCell) or both, or control rat IgG
(Sigma). Control or depleting antibodies were used in both control and chemerin-expressing (HC) tumors as indicated (n = 5–6/group). (E) Depletion of blood T cell
subsets was confirmed in each experiment at either day−1 or day 0 (time of inoculation). Graphs show mean/SEM from representative experiments with similar results
(n = 4 experiments for NK depletion, n = 2 experiments each for T cell depletion, RAG KO studies). P-values are indicated from 2-tailed unpaired t-tests between
indicated groups at time of euthanization.
significant effect on tumor intrinsic proliferation or phenotype
in vitro, though this may be a function of specific tumor types
as well as the presence or absence of chemerin receptors on
tumor cells, as others have shown direct effects of chemerin on
tumor cells (45, 46, 48, 49). RARRES2-transduced EMT6 clones
with lower expression of chemerin grew similarly to control
cells in vivo, suggesting that in this model adequate expression
and secretion of chemerin within the TME is necessary to
successfully establish the concentration gradient necessary to
recruit leukocytes.
The EMT6 mouse tumor model has recently been shown
to recapitulate an “immune excluded” tumor phenotype with
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FIGURE 6 | Proposed model for role of chemerin in tumor immune surveillance and suppression. Chemerin/RARRES2 is down-regulated in breast and other tumors
compared to their normal tissue counterparts. Data from our mouse tumor models show that forced over-expression of chemerin within the tumor microenvironment
(TME) results in an increase in tumor-infiltrating leukocyte effector subsets (NK cells, CD8+ T cells) that are required to suppress tumor growth. Strategies focused on
augmenting chemerin in the TME may represent an attractive strategy to increase effector cell composition within the tumor and potentially favorably impact the effect
of existing immunotherapies such as checkpoint inhibitors in otherwise treatment-refractory tumors.
exclusion of CD8+ T cells from the tumor parenchyma,
often seen in human tumors such as urothelial cancers (31).
Importantly, we found meaningful increases in both NK and T
cells within chemerin-expressing tumors compared to controls,
similar to our findings in the melanoma model. Depletion
studies indicate important roles for NK and CD8+ T cells in
mediating the tumor suppressive effects of chemerin in this
model, not surprisingly as supportive roles of NK cells in
T cell function and the adaptive immune response are well
described (53–56). Though chemerin does not seem to directly
recruit CD8+ T cells via CMKLR1 interactions in this model,
there is compelling evidence in the literature to suggest that
NK cells mediate various functions that enhance CD8+ T
cell cytolytic activity; for example, NK cells have been shown
to moderate CD8+ T cell priming during influenza A viral
infection and activate CD8+ T cell anti-tumor activity in the
YAC-1 mouse lymphoma model (57, 58). Other studies have
found that intratumor NK cell recruitment induces further
leukocyte infiltration into the tumor (59), together articulating
the point that chemerin may not need to act directly on
CD8+ T cells to play a role in chemerin-dependent tumor
growth inhibition. Additionally, ongoing studies include the
impact of chemerin expression on the establishment of immune
memory as well as the development of metastatic disease in
this model.
Our de novo studies of human breast tissues using two
independent cohorts of normal, IDC, and ILC samples across
two assay platforms confirm large publicly available microarray
datasets showing RARRES2 is significantly down-regulated
in breast malignancies. Additionally, analysis of two mRNA
microarray datasets showed that reduced chemerin levels
significantly correlated with poor survival outcomes. In our
in vivo experiments, we did not directly assess the effects
of chemerin down-regulation/silencing during tumorigenesis
in the EMT6 model. Rather, we focused on studying the
potential therapeutic activity of restoring and/or overexpressing
chemerin in the TME. Additional tumor studies are needed
in animals with spontaneous carcinomas to determine whether
chemerin down-regulation in the TME correlates with poor
survival and thus models the clinical results we described in
Figures 1, 2. Given the variability within and across tumor types,
evaluation of chemerin/RARRES2 and receptor expression will
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be important prior to pursuing human translational studies.
Importantly, recently published data provides a mechanistic
link between chemerin and PTEN expression and function
in hepatocellular carcinoma (48), suggesting chemerin may
have other tumor suppressive mechanisms of action in
addition to the recruitment of immune effector cells into
the TME. Taken together our data elucidate mechanistic
insights into the role of chemerin in breast tumor suppression
and provide rationale for translational studies in human
breast cancer.
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